I figure they'll be doing an 8 to 10X split at anywhere between 120 and 150. And a reverse split on Dust to get them back to close parity.
Yes, it is volatile. The Miners have been smacked down for 5 years. Gold has been hated, miners have been hated. Its an election year with Yellen appointed by a Democratic President. The Dems won't allow any rate hikes that might start to unravel this tenuous ball of lies the BLS has created with their insanely manipulated statistical restatements of reality (figures don't lie but liars figure). Goldman was short the gold trade last month, and had their muppets short, they are now covering. The retail public still isn't aware of the movement in this sector, and since they are always the last in and last out, there should be a lot of buying from that direction. We, just this week, admonished the rest of the World that they had better not try to devalue their currencies against the Greenback or else! So, the trend is very bullish, the only tootsie roll in the punch bowl will be further currency devaluations by other Countries, making the Greenback the Belle of the Ball, or a rate hike by the Fed that would pull money out of the Market--and that isn't going to happen with the elections 7 months away.
So, yep, we could see some terrifying one day movements, but the trend is as clearly your friend. Plus, biotech has been sucking wind, tech is weak, manufacturing is falling off a cliff, time for sector rotation.
With the storming of the Parliament in Baghdad, IRAQ is looking pretty precarious. I expect panic buys in India and Asia on Sunday evening and that will carry over to a gap up on Monday in both the Oilies and the Miners.
You must have some serious stones to be selling naked calls on this Monster. Congrats if you can do it, but that would generate more anxiety than my nerves can take.
Yeah, serious end of day buying. It sure looked like Insto shorts panicking. Still Huge Insto Short interest l. If we get a 20% pull back on Monday the Shorts will climb on, only to face a buying rush from retails and Asia.
This is one sweet short pressing. The only thing that will end it is higher interest rates, and that isn't going to happen in an election where all mainstream politicos are sweating and looking for exit contingencies if Trump does get the nomination.
I traded it in and out around 19. Then came back in around 30 with the last buy in the high 70's. Been holding and not trading, as no matter what everyone sez, you can't trade this thing in this environment. Even with the decay, it's a buy and hold until something really unexpected occurs. That being said, you can't over allocate or it will send you to the nut house or to the bar. I'm happy with a modest 500 shares, just riding it and not worry about the day to day moves.
Nice find. So, the Asian consumer thought the price had moved too high too quick and decided to wait for a fall back....ooops, I smell a panic buying rush coming from the Asian Herd. That coupled with the historic short positions held by the Instos and the total unawareness of Joe Retail of the move in gold and their always piling in late and buying on the way up and, of course, the ultimate confirmation that we are in for a massive move up......wait for it... Canada liquidates all of its gold reserves.
Oh, so you are sure the Yellenator will no longer move to devalue the dollar???? If the dollar remains strong everything gets worser. The only fly in the ointment is China's move to control gold in Yuan. Now, pessimist will think they'll try and make gold cheap again to accumulate more to add to their massive reserves as they position the Yuan to be backed in gold and thus become a currency in demand.
A small wry chuckle can be had at the expense of the poor Cannuks who just sold all of their reserves.
Paradise, you do realize that these class action law firm #$%$ file class actions suits on every stock in pharma/bio space that has a major knock back in share price. And, they will tell you anything to get you to sign up. If you get 1/20th of your money back after the class action lawyer #$%$ get their fat hourly rates you can count yourself lucky.
Take a look at who makes up the FDA board. There are "independent scientist" and there are executives from the Industry. Now, think about how the industry would feel about TRXC!!!!
Exactly. The FDA will work on it's own time frame. There has been no notice for TRXC to head back to the skunk works and tweak their Bot. Things are moving as they were expected to...
The FDA advised the Company that it has not yet concluded the review of the Company's 510(k) submission and provided an update on the status of the filing. The Company has updated its timing expectations and now expects to receive a decision from the FDA by mid-April, 2016. The Company previously expected a decision from the FDA in the first quarter of 2016.
"We have been engaged in constructive dialogue with the FDA throughout the entire submission process," said Todd M. Pope, President and Chief Executive Officer of TransEnterix. "We appreciate the proactive exchange with the FDA and look forward to their decision, and continue to expect clearance for the SurgiBot."
Yeah, I never use submitted stops, and in this case I did. Stops taken out at $4.98, but after seeing no news I was able to buy back my position at $4.95.
Decay is not exactly relevant in this Market. So far in this year it is possible to trade NUGT in short term swings, but excellent money is being made just buying and holding. We all know the US wants to weaken the Greenback, that, coupled with ZIRP and NIRP provides a clear message that gold will become more "dear" to investors and Countries (except to crazy Canadians) all over the World. I also believe the yesterday's filing of two class action lawsuits against the Gold Cartel in Canada for over a billion will gather steam and publicity further focusing investors on Gold.
oDER April 15, 2016 8:00 a.m. to 5:00 p.m. Hilton Washington DC North/
Gaithersburg, The Ballrooms
620 Perry Pkwy.
Gaithersburg, MD 20877
Well, that is convoluted thinking. First off, they to get approval. It is expected, based, amongst other things, due to the previous interaction with the FDA.
Then they can sell the darn things. And, the application is much broader than many here want to admit. I'm sure there are all sorts of smallish hospitals that would love to advertise they have a unit. They'll get orders much faster than you are suggesting.
The biggest danger is the political nature of the FDA.
The Risks Behind TransEnterix
By The Wall Street Fox → Monday, March 16, 2015
Considering the fact that TransEnterix makes up 55% of my overall investment portfolio, it's important to thoroughly understand all possible risks behind the company. In my opinion, here are the potential risks, and my reasoning against them.
#1. Perhaps the biggest, most obvious risk of them all: The FDA denies the SurgiBot approval.
TransEnterix formally received feedback from the FDA on its upcoming 510(k) filing in the summer of 2014 through a pre-submission filing, which was filed in March 2014. The company essentially submitted a rough draft of the SurgiBot 510(k) filing, the FDA told them what worked and what didn't, and TransEnterix is now acting accordingly and expects to submit the 510(k) filing by July 1.
The FDA desperately wants competition in the surgical robotic market. Nobody benefits from a monopoly except for the company in control, which in this case is Intuitive Surgical. Intuitive has been selling the Da Vinci since 2000. Competition brings lower pricing, faster innovation, and more choices for consumers. In the case of robotic surgery, it means hospitals won't be paying an arm and a leg for a surgical robot, surgeons will quickly adopt better technology that is constantly improving, and less patients will be subject to potentially life threatening complications during surgical procedures due to the inclusion of tactile feedback in the SurgiBot, among other features. Here's an excerpt from a law firm's website that specializes in robotic surgery lawsuits:
Da Vinci robot surgical complications can occur because the surgeon is given no tactile feedback to gauge the grip of the robot probes. As a result, the manipulation arms can accidentally tear through body tissues, sever small blood vessels, or puncture organs. In some cases, these errors will not be discovered for hours or days after the operation has been completed, when the patient begins exhibiting symptoms that something has gone wrong.
TransEnterix's previous product, the SPIDER System, is considered a similar device to the SurgiBot, which means that TransEnterix is allowed to include human data from the 4,500+ surgical cases already performed with the SPIDER in the SurgiBot 510(k) submission. The SurgiBot System utilizes the same core technology found in the SPIDER System: a single incision operating platform that includes 4 channels where flexible or rigid instruments and a camera can be inserted at the operating site. The SPIDER received 510(k) approval in 2009, and European CE mark the following year.
#2. The FDA will say that the SurgiBot should not be classified as a class II medical device, which would result in the need for human clinical data and delay the approval of the SurgiBot by ~3 months.
I cannot find a single surgical robot that is not FDA approved as a Class II medical device, from Intuitive Surgical's da Vinci System, and its single port add ons, to Stereoaxis' Vdrive, to Mako Surgical's RIO Robotic Arm (there are plenty more) IMRIS' Symbis will be added to this list if it receives approval in mid 2015, as will TransEnterix's Surgibot.
#3. The Intutive Surgical single port offerings (da Vinci Sp and Xi) will prove to be stiff competition to the SurgiBot.
Both single port add ons for the da Vinci System still lack tactile feedback, still puts the surgeon outside of the sterile field away from the patient, still has high capital costs of ~$2 Million, and is still a massive machine that cannot be easily moved between operating rooms.
The Surgical Robotic market is still growing, and remains unsaturated. Less than 1% of the 5,000+ private U.S. surgery centers are equipped with a surgical robot, and a large majority of the 3,000 U.S. Hospitals that have less than 500 beds do not have a surgical robot. Clearly, the market is big enough for a few players. Also, don't forget about the international market.
#4. TransEnterix will be subject to the same costly personal injury/accidental death lawsuits that Intutive Surgical is constantly dealing with.
While this is no doubt a possibility, the fact that the SurgiBot includes tactile feedback, 3D vision for both the surgeons and assistants, and is a patient side system, a lot of this risk is mitigated. Having internal triangulation, true left hand/right hand control, and the ability to clutch instruments into an ergonomic position, along with several other safety features, also doesn't hurt.
#5. Management will have a tough time executing its strategic goals and selling the device.
TransEnterix has high quality management. CEO Todd Pope was president of a multi billion dollar division within Johnson and Johnson, CFO Joseph Slattery played an instrumental roll in the growth of Digene Corp, and Mohan Nathan spent a considerable amount of time at Intuitive Surgical. The nine member board is also an impressive team, I suggest you read their bios on the TRXC website.
Management at TransEnterix has been able to convince Billionaire Dr. Phillip Frost and Dr. Jane Hsiao, six different healthcare oriented venture capital firms, BlackRock, Fidelity, Putnam Investment Managers, and sovereign wealth funds in the Middle East to invest, among others. If TRXC management could convinc these high profile investors that they can execute their strategy, they could (and did) convince me. These investors own roughly 65% of TransEnterix.
Todd Pope has already indicated that the company is constantly receiving inbound calls about the SurgiBot, and is also receiving strong interest for the product from South America, Japan, Europe, and the Middle East. Pope has also signaled that the first 50 purchase orders for the SurgiBot will be represented by large hospital teaching institutions. Given the SurgiBot's initial $500,000 price tag, it shouldn't be a tough sell.
#6. Surgical Robotics in general will receive increasing scrutiny from the public and their supposed benefits will be questioned, especially given the tight capital spending environment at hospitals following the passage of the Affordable Care Act (ACA).
TransEnterix plans to release a white paper on the results of the 4,500+ surgeries conducted with the SPIDER System that should refute critics of single port surgery. Cold hard data should help its case.
#7. TransEnterix will need to raise more funds in the future and dilute current shareholders.
Given my long term investment horizon for TransEnterix, I do not necessarily view this as a risk. Capital infusions are required to expand business operations, and TRXC will have lots of growing to do. I do acknowledge that any secondary offering (such as the current $25M ATM offering) will serve as short term weakness for the stock performance.
#8. TransEnterix will be attacked by short sellers in the event of any meaningful pop in stock price.
It's tough to argue against this one. TRXC is already heavily shorted, with more than 1 million shares sold short as of today. It is in the nature of shorts to bet against companies that have a high P/S ratio with no earnings and a large accumulated deficit. Only walking the walk can route this risk, which can take some time.
#9. TransEnterix faces lawsuits for patent infringement from competing companies.
VP Kathleen Frost oversees patent/legal/regulatory work for the company and has more than 25 years of experience in the medical device industry. Frost's previous experience includes work at the FDA, where she evaluated 510(k), Investigational Device Exemption, and Premarket Approval submissions as a member of the Office of Medical Device Evaluation. This is also a strong point to add to the first potential risk at the top of this post regarding FDA denying approval of the SurgiBot. Frost adds tremendous insight into the FDA approval of 510(k) products for TransEnterix. She also specializes in patents and works to make sure TransEnterix is not infringing any existing patents and helps file patents.
Intuitive Surgical's patents expire in 2016, so they should not pose a threat from an IP standpoint, not to mention the technology behind these two companies is vastly different, so there probably would not be any patent infringement in the first place. TransEnterix has more than 10 patents and some will not expire until 2035.
Am I missing any potential risks that you see? Let me know and I will include them and my reasoning in an updated post